CMA investigates Vifor Pharma to safeguard essential anaemia treatment

Summary:

The Competition and Markets Authority (CMA) has launched an investigation into Vifor Pharma, a global pharmaceutical company, over suspected anti-competitive conduct in the supply of intravenous (IV) iron deficiency treatments for National Health Service (NHS) patients in the UK. The CMA will assess whether Vifor has restricted competition by making misleading claims about its rival Monofer, a high-dose IV iron deficiency treatment supplied by Pharmacosmos. The investigation aims to determine if Vifor's conduct could harm patients by stifling competition in the supply of vital iron treatments to the NHS.